Disease | NIH | Therapeutics
NIAID awarded BioCryst $44 million contract to advance development of galidesivir
On Aug. 31, 2020, BioCryst Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases (NIAID) had…
-
-
Moderna confirmed discussions with the MHLW to supply Japan with 40 million doses of mRNA vaccine against COVID-19
On Aug. 28, 2020, Moderna confirmed that the Company was engaged in discussions with the Ministry of Health,…
-
AIM ImmunoTech decreased SARS-CoV-2 infectious viral yields by 90% using new in vitro model
On Aug. 27, 2020, AIM ImmunoTech announced that it had identified an effective in vitro model at The…
-
BioNTech and Fosun Pharma to potentially supply 10 Million doses of BNT162 mRNA-based vaccine candidate against SARS-CoV-2
On Aug. 27, 2020, Pfizer and Shanghai Fosun Pharmaceutical announced an intended collaboration to supply 10 million doses…
-
Assembly Biosciences and Arbutus announced collaboration to evaluate combination of core inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in patients with Chronic Hepatitis B Virus Infection
On Aug. 27, 2020, Assembly Biosciences and Arbutus Biopharma announced that the companies have entered into a clinical…
-
Sorrento announced agreement to acquire SmartPharm and develop gene-encoded therapeutic antibodies for COVID-19 and cancer therapeutics
On Aug. 20, 2020, Sorrento Therapeutics and SmartPharm Therapeutics announced the signing of a merger agreement under which…
-
Pfizer and BioNTech shared positive early data on lead mRNA vaccine candidate BNT162b2 against COVID-19
On Aug. 20, 2020, Pfizer and BioNTech shared additional Phase 1 safety and immunogenicity data from their U.S….
-
Bio-Techne and Leica Biosystems are acceleratied disease research with RNAscopeﾙ COVID-19 probes and the BOND RX
On Aug. 19, 2020, Bio-Techne in partnership with Leica Biosystems, announced the automation of RNAscopeﾙ COVID-19 probes on…
-
Pfizer and BioNTech announced publication of peer-reviewed data from phase 1/2 study of mRNA-based vaccine candidate
On Aug. 12, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from their BNT162 mRNA-based vaccine development…
-
Moderna announced supply agreement with U.S. Government for initial 100 million doses of mRNA vaccine against COVID-19
On Aug. 11, 2020, Moderna announced that the U.S. government had secured 100 million doses of mRNA-1273. The…
-
NIH-Moderna investigational COVID-19 vaccine showed promise in mouse studies
On Aug. 5, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that the investigational vaccine…
-
Pfizer and BioNTech to supply Canada with their BNT162 mRNA- based vaccine candidate
On Aug. 5, 2020, Pfizer Canada and BioNTech announced an agreement with the Government of Canada to supply…
-
Pfizer and BioNTech announced an agreement with the MHLW in Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate
On Jul. 31, 2020, Pfizer and BioNTech announced an agreement with the Ministry of Health, Labour and Welfare…
-
Veracyte and MAVIDx announcd agreement for MAVIDx to develop ultra-high volume COVID-19 testing on the nCounter System
On Jul. 29, 2020, Veracyte and MAVIDx announced an agreement for MAVIDx to develop ultra-high throughput genomic testing…
-
FDA authorized Quest Diagnostics lab method designed to increase COVID-19 molecular diagnostics capacity
On Jul. 29, 2020, Quest Diagnostics announced that the FDA had granted emergency use authorization for a new…
-
Moderna announced publication in the NEJM of non-human primate preclinical viral challenge study of its mRNA vaccine against COVID-19
On Jul. 28, 2020, Moderna announced a preclinical study evaluating mRNA-1273, its vaccine candidate against COVID-19, was published…
-
Phase 3 clinical trial of investigational vaccine for COVID-19 began
On Jul. 27, 2020, the National Institutes of Health (NIH) announced that a phase 3 clinical trial designed…
-
Amyris and the Infectious Disease Research Institute partnered to advance novel RNA vaccine platform beginning with COVID-19 application
On Jul. 27, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a binding…
-
Moderna announced phase 3 COVE study of mRNA vaccine against COVID-19 (mRNA-1273) began
On Jul. 27, 2020, Moderna announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against…
-
Moderna announced expansion of BARDA agreement to support larger phase 3 program for vaccine (mRNA-1273) against COVID-19
On Jul. 26, 2020, Moderna announced a modification to its contract with the Biomedical Advanced Research and Development…
-
GSK and CureVac announced strategic mRNA technology collaboration
On Jul. 21, 2020, GlaxoSmithKline and CureVac announced the signing of a strategic collaboration agreement for the research, development,…
-
Experimental coronavirus vaccine reported safe and produces immune response
On Jul. 21, 2020, researchers from the National Institutes of Health (NIH) announced that early results from the…
-
Experimental Coronavirus vaccine is safe and produced immune response
On Jul. 21, 2020, National Institutes of Health (NIH) researchers reported early results from the first COVID-19 vaccine…
-
HDT BIOﾒs COVID-19 vaccine candidate HDT-301 induced neutralizing antibody responses after single injection
On Jul. 20, 2020, scientists at HDT Bio, PAI Life Sciences, and the University of Washington announced they…
-
Pfizer and BioNTech announced sgreement with the UK for 30 million doses of mRNA-based vaccine candidate against SARS-CoV-2
On Jul. 20, 2020, Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million…
-
Pfizer and BioNTech announced early positive update from German phase 1/2 COVID-19 vaccine study
On Jul. 20, 2020, BioNTech and Pfizer announced initial data from their ongoing German Phase 1/2, open-label, non-randomized,…
-
Placenta lacks major molecules used by SARS-CoV-2 virus to cause infection
On Jul. 14, 2020, a study by NIH researchers reported the placental membranes that contain the fetus and…
-
Experimental COVID-19 vaccine safe, generated immune response
On Jul. 14, 2020, an investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus…
-
Moderna announced publication in The New England Journal of Medicine of interim results from phase 1 study of its mRNA vaccine against COVID-19
On Jul. 14, 2020, Moderna announced the publication of an interim analysis of the open-label Phase 1 study…
-
Pfizer and BioNTech granted FDA Fast Track Designation for two investigational mRNA-based vaccine candidates against SARS-CoV-2
On Jul. 13, 2020, Pfizer and BioNTech announced that two of the companiesﾒ four investigational vaccine candidates from…
